<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01198808</url>
  </required_header>
  <id_info>
    <org_study_id>IBT-1</org_study_id>
    <nct_id>NCT01198808</nct_id>
  </id_info>
  <brief_title>Tumorspecific T-cell Immunity in Bladder Cancer as Prognostic Marker</brief_title>
  <official_title>Prospective Characterization of Tumor-specific T-cell Immunity in Muscle-invasive Bladder Cancer and Its Correlation With Clinical Parameters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bladder cancer is generally susceptible to immunotherapeutic measures. The investigators will
      characterize 40 patients with muscle-invasive bladder cancer regarding the existence and
      frequency of tumorspecific T-cells and regulatory T cells. The found data will be correlated
      to clinical data such as the cancer-specific survival and the response to chemotherapy.

      It is hypothesized that those patients with a high number of Tregs and no tumor-specific
      T-cells have a worse prognosis.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2010</start_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Bladder Cancer</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will consist of patients with muscle-invasive bladder cancer, who are
        referred to the university hospital: Krankenhaus rechts der Isar der Technischen
        Universität München
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed muscle-invasive urothelial carcinoma

          -  Age &gt; 18 years

          -  Hemoglobin &gt; 10g/dl

          -  Signed Informed Consent

          -  Karnofsky index &lt; 70%

        Exclusion Criteria:

          -  Clinically relevant second malignancy

          -  Severe comorbidities (e.g. NYHA III, end-stage renal disease)

          -  Chronic infectious disease (HIV, Tuberculosis)

          -  Immunosupression

          -  Severe psychiatric diseases

          -  Blood donation in the last 4 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Horn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Urology, Technische Universität München</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Urologische Klinik der Technischen Universität München</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2010</study_first_submitted>
  <study_first_submitted_qc>September 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2010</study_first_posted>
  <last_update_submitted>January 16, 2012</last_update_submitted>
  <last_update_submitted_qc>January 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bladder cancer</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>T cells</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Tumor-specific immunity in bladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

